Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 11/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.40 |
| ▸ | NPY1R | P25929 | 8/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.39 |
| ▸ | NPY2R | P49146 | 5/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etelcalcetide SCHEMBL21982605 | 0.93 | SIRT5 (0.44) | NPY4RNPY5RNPY1RSIRT5NPY2R | |
| Etelcalcetide SCHEMBL20869503 | 0.93 | SIRT5 (0.44) | NPY4RNPY5RNPY1RSIRT5NPY2R | |
| Etelcalcetide SCHEMBL20869502 | 0.93 | SIRT5 (0.44) | NPY4RNPY5RNPY1RSIRT5NPY2R | |
| Etelcalcetide SCHEMBL22578458 | 0.92 | SIRT5 (0.43) | NPY4RNPY5RNPY1RSIRT5NPY2R | |
| Hydrochloric Acid SCHEMBL28425407 | 0.92 | SIRT5 (0.43) | NPY4RNPY5RNPY1RSIRT5NPY2R | |
| Etelcalcetide SCHEMBL22578464 | 0.92 | SIRT5 (0.43) | NPY4RNPY5RNPY1RSIRT5NPY2R | |
| SCHEMBL24991307 | 0.88 | SIRT5 (0.44) | NPY4RNPY5RNPY1RSIRT5NPY2R | |
| Etelcalcetide SCHEMBL22578460 | 0.87 | SIRT5 (0.49) | NPY4RNPY5RNPY1RSIRT5NPY2R | |
| SCHEMBL16690663 | 0.81 | NPY4R (0.48) | NPY4RNPY5RNPY1RSIRT5NPY2R | |
| SCHEMBL16690636 | 0.81 | NPY4R (0.48) | NPY4RNPY5RNPY1RSIRT5NPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018044468-A1 | COMBINATION OF LOW DOSE 2-METHYLENE-19-NOR-(20S)-1α, 25-DIHYDROXYVITAMIN D3 AND CALCIMIMETICS TO TREAT SECONDARY HYPERPARATHYROIDISM | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2018-03-08 | — | — | WO | disclosed |
| US-20180055856-A1 | COMBINATION OF LOW DOSE 2-METHYLENE-19-NOR-(20S)-1ALPHA, 25-DIHYDROXYVITAMIN D3 AND CALCIMIMETICS TO TREAT SECONDARY HYPERPARATHYROIDISM | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2018-03-01 | — | — | US | disclosed |
| US-20180055856-A1 | COMBINATION OF LOW DOSE 2-METHYLENE-19-NOR-(20S)-1ALPHA, 25-DIHYDROXYVITAMIN D3 AND CALCIMIMETICS TO TREAT SECONDARY HYPERPARATHYROIDISM | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180055856-A1 | COMBINATION OF LOW DOSE 2-METHYLENE-19-NOR-(20S)-1ALPHA, 25-DIHYDROXYVITAMIN D3 AND CALCIMIMETICS TO TREAT SECONDARY HYPERPARATHYROIDISM | PTH1R, CYP24A1, VDR | NPY4R 1856/4885NPY5R 812/4885NPY1R 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.